LEXX (Lexaria Bioscience) Net Income (Continuing Operations): $-7.74 Mil (TTM As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LEXX Lexaria Bioscience Corp LEXX
48 GF Score
Price $3.17
GF Value $5.36
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lexaria Bioscience Net Income (Continuing Operations)?

Lexaria Bioscience LEXX -2.16% 48 Net Income (Continuing Operations) is $-7.74 Mil as of May. 2026. GuruFocus rates LEXX with a GF Score™ of 48/100 and a GF Value™ of $5.36 (Possible Value Trap). The stock has 4 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Lexaria Bioscience's Net Income (Continuing Operations) for the three months ended in May. 2026 was $-1.99 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in May. 2026 was $-7.74 Mil.

Lexaria Bioscience  (NAS:LEXX) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Lexaria Bioscience Net Income (Continuing Operations) Related Terms

Lexaria Bioscience Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Lexaria Bioscience's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexaria Bioscience Net Income (Continuing Operations) Chart

Lexaria Bioscience Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.16 -7.38 -6.71 -5.81 -11.91

Lexaria Bioscience Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.79 -2.70 -1.60 -1.45 -1.99
LEXX
48GF Score
Lexaria Bioscience Corp LEXX
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexaria Bioscience Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-7.74 Mil mean?
Lexaria Bioscience (LEXX) has a Net Income (Continuing Operations) of $-7.74 Mil as of May. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Lexaria Bioscience and its competitors.
Is Lexaria Bioscience's Net Income (Continuing Operations) too high?
Lexaria Bioscience's current Net Income (Continuing Operations) is $-7.74 Mil. Overall, Lexaria Bioscience has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Net Income (Continuing Operations) compare to TPST and LPCN?
Lexaria Bioscience's Net Income (Continuing Operations) of $-7.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Lexaria Bioscience and its competitors. Lexaria Bioscience's current Net Income (Continuing Operations) is $-7.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Possible Value Trap. The stock's GF Value™ is $5.36, compared to a current price of $3.17 — trading 40.9% below its estimated fair value. The current Net Income (Continuing Operations) is $-7.74 Mil. Lexaria Bioscience's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Net Income (Continuing Operations) is $-7.74 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lexaria Bioscience (LEXX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be undervalued. The current stock price of $3.17 is trading 40.9% below its estimated GF Value™ of $5.36. GuruFocus considers Lexaria Bioscience to be Possible Value Trap.

Key valuation signals for LEXX:

  • Net Income (Continuing Operations): $-7.74 Mil
  • GF Value™: $5.36 vs. price of $3.17 (40.9% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lexaria Bioscience Business Description

Address 740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
48GF Score

Get the complete analysis for LEXX

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.17
Price
$5.36
GF Value